Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Table 2 Patient Characteristics, Response and Steroid Dose

Pt #	Grade	OR	KPS	# of cycles of pembro	MGMT Status	IDH Status	1p/19q	ML	Steroids at initiation	Steroid dose at initiation (in prednisone equivalence)			# of cycles with steroids	Con Bev	Prev Bev
Pt #	Grade	OR	KPS	# of cycles of pembro	MGMT Status	IDH Status	1p/19q	ML	Steroids at initiation	0	<20	≥20	# of cycles with steroids	Con Bev	Prev Bev
1	III	PR	90	4	unmethylated	WT	N/A	6	N	X			2	Y	Y
2	IV	PR	80	4	unmethylated	N/A	N/A	6	Y			X	1	Y	N
3	III	SD	90	14	methylated	WT	intact	6	N	X			0	N	N
4	III	SD	70	10	unmethylated	MUT	N/A	3	Y			X	1	Y	Y
5	IV	SD	90	14	unmethylated	WT	N/A	12	N	X			5	Y	Y
6	IV	SD	100	4	methylated	N/A	N/A	13	N	X			0	N	Y
7	IV	SD	100	1	N/A	WT	N/A	N/A	Y			X	1	Y	Y
8	III	PD	90	6	N/A	MUT	co-del	5	Y		X		1	N	N
9	III	PD	60	5	N/A	MUT	co-del	58	Y		X		0	Y	Y
10	III	PD	60	3	unmethylated	MUT	N/A	7	N	X			2	N	N
11	III	PD	70	3	unmethylated	WT	N/A	5	Y		X		3	Y	Y
12	III	PD	90	2	unmethylated	WT	intact	15	Y		X		2	Y	N
13	III	PD	90	2	unmethylated	MUT	N/A	7	Y			X	2	Y	Y
14	III	PD	N/A	1	methylated	MUT	N/A	5	N	X			0	N	Y
15	IV	PD	90	5	methylated	MUT	N/A	11	Y			X	2	N	N
16	IV	PD	60	5	unmethylated	WT	intact	10	Y			X	2	Y	Y
17	IV	PD	50	4	N/A	N/A	N/A	N/A	N	X			0	Y	Y
18	IV	PD	90	3	N/A	MUT	N/A	9	Y			X	3	Y	Y
19	IV	PD	90	3	unmethylated	N/A	N/A	4	Y			X	1	Y	Y
20	IV	PD	90	3	N/A	N/A	N/A	N/A	N	X			1	Y	Y
21	IV	PD	70	2	unmethylated	WT	N/A	13	Y		X		2	Y	Y
22	IV	PD	80	2	unmethylated	MUT	N/A	5	N	X			0	Y	Y
23	IV	PD	80	2	N/A	WT	N/A	N/A	N	X			1	Y	Y
24	N/A	PD	70	2	N/A	N/A	N/A	N/A	N	X			1	Y	Y
25	IV	N/A	60	1	N/A	MUT	intact	19	Y			X	1	Y	Y

Abbreviations: Pt: Patient; OR: Objective response; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; KPS: Karnofsky performance score; Pembro: pembrolizumab; N/A: not applicable or unknown; MGMT methylated: methylated; MGMT unmethylated: unmethylated; IDH mutant: MUT; IDH wild type: WT; 1p19q intact: intact; 1p19q codeleted: Co-del; ML: mutational load by MSK impact; Y: yes; N: no; X: indicates steroid dose at initiation; Con Bev: Concomitant bevacizumab; Prev Bev: previously progressed on bevacizumab treatment